Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration-Resistant Prostate Cancer Patients Metastatic to Bone (EORTC-1333-GUCG/PEACE III)

Supporting Patients Receiving Radium-223 for mCRPC - Fred Saad

The NCCN Guidelines on the Use of Radium-223 in Prostate Cancer - Tanya Dorff

Optimal Patient Selection for Treatment with Radium-223 in mCRPC Towards Improved Overall Survival and Improved Quality of Life - Brenda Martone

The Importance of Bone-Protecting Agents When Treating mCRPC with Bone Metastatic Disease The PEACE III Trial – Silke Gillessen

Decreased Fracture Rate When Adding Bone Protecting Agents to Radium-223: PEACE III- Bertrand F. Tombal

Press Releases

Official Announcements on Clinical Developments

Bayer Announces Positive Topline Results for NUBEQA® (Darolutamide) from Phase III Trial in Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
Results were consistent with NUBEQA’s established safety profile with no new signals observed
NUBEQA now has positive mHSPC data both with and without docetaxel based on two pivotal Phase III studies
Bayer plans to present the pivotal data at a forthcoming scientific congress and discuss these data with the U.S. Food and Drug Administration (FDA) for regulatory approval

Conference Coverage

Conference Highlights Written by Physician-Scientist

PSMA PET and RLT 2024: The Role of Radium-223 in the Setting of PSMA PET

ASCO 2021: Decreased Fracture Rate by Mandating Bone Protecting Agents in the EORTC 1333/PEACEIII Trial Combining Radium-223 with Enzalutamide Versus Enzalutamide Alone: An Updated Safety Analysis

ASCO 2021: Decreased Fracture Rate by Mandating Bone Protecting Agents in the EORTC 1333/PEACEIII Trial Combining Ra223 with Enzalutamide Versus Enzalutamide Alone: An Updated Safety Analysis

Presented by Silke Gillessen, MD

Beginning with the introduction of docetaxel for metastatic castration resistant prostate cancer (mCRPC) in 2004, there has been a dramatic and rapid proliferation of systemic therapy options in advanced prostate cancer including a number of novel hormonal therapies (including abiraterone acetate and enzalutamide), Read More

ASCO GU 2018: Enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic CRPC patients metastatic to bone (PEACE III)

Transformative Evidence

Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration-Resistant Prostate Cancer Patients Metastatic to Bone (EORTC-1333-GUCG/PEACE III)

Login